Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
127 hedge funds and large institutions have $205M invested in Antares Pharma, Inc. in 2019 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 46 increasing their positions, 34 reducing their positions, and 18 closing their positions.
35% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 34
2% less capital invested
Capital invested by funds: $209M → $205M (-$3.84M)
6% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 18
4% less funds holding
Funds holding: 132 → 127 (-5)
14% less call options, than puts
Call options by funds: $1.63M | Put options by funds: $1.89M
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cortina Asset Management
Milwaukee,
Wisconsin
|
+$3M |
| 2 |
BlackRock
New York
|
+$2.88M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
+$1.98M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.48M |
| 5 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
+$797K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$12.4M |
| 2 |
JAM
JW Asset Management
Miami Beach,
Florida
|
-$4.46M |
| 3 |
Morgan Stanley
New York
|
-$3.37M |
| 4 |
BC
Broadfin Capital
New York
|
-$2.6M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.98M |
ATRS Hedge Fund Activity: Q2 2019 in Review
127 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q2 2019, worth a combined $205M — down 1.8% from $209M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of ATRS and 17 opened new positions — a net loss of 1 holder — while 34 trimmed existing stakes and 46 added.
The largest buyer was Cortina Asset Management, adding an estimated $3M. The largest seller was Armistice Capital, cutting an estimated $12.4M.
- 127 institutional investors held Antares Pharma, Inc. (ATRS) as of Q2 2019, down from 132 in Q1 2019.
- Funds reported $205M of Antares Pharma, Inc. stock for Q2 2019, down 1.8% quarter-over-quarter.
- 17 funds opened new Antares Pharma, Inc. positions in Q2 2019 and 18 closed out, a net change of -1 holder.
- The largest Antares Pharma, Inc. buyer in Q2 2019 was Cortina Asset Management, an estimated $3M added.
- The largest Antares Pharma, Inc. seller in Q2 2019 was Armistice Capital, an estimated $12.4M sold.
Based on aggregated 13F filings for Q2 2019.